Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood treatment revive Low-Ovarian-Response? new study investigates

NCT ID NCT07376460

Knowledge-focused Sponsor: Instituto Valenciano de Infertilidad, IVI Alicante Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will analyze blood samples from 10 women with poor ovarian response who are undergoing a treatment called StemCell Regenera. The treatment combines platelet-rich plasma (PRP) with a drug (filgrastim) that mobilizes stem cells from bone marrow into the blood. Researchers will compare the PRP before and after stem cell mobilization to understand which proteins and factors might help reactivate the ovaries. The goal is to learn more about how this approach works at a cellular level, not to directly test a new therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Platelet-rich plasma (PRP) and filgrastim (stem cell mobilizer)
What this could lead to
If successful, this could reveal key factors that help reactivate ovaries in women with poor ovarian response, potentially improving future fertility treatments.
What could go wrong
This is a very early, small study (10 participants) focused on lab analysis, not patient outcomes. It may not lead to any direct treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients from IVI Alicante who decide to undergo the ovarian reactivation treatment "StemCell Regenera" at the clinic for improving ovarian function

Ages

18 to 43 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 18 and 43. * Patients diagnosed with poor ovarian response (POR) or low ovarian reserve according to Bolonia criteria (ESHRE). * Patients who are indicated for a StemCell Regenera procedure with the use of granulocyte colony-stimulating factors (Filgrastim). * Patients who agree to participate and sign the informed consent form. Exclusion Criteria: * Patients over the age of 43. * Patients with only one ovary. * Patients with an autoimmune or haematological disorder. * Patients currently undergoing treatment with anticoagulant drugs. * Patients who are allergic to Filgrastim, the granulocyte colony-stimulating factor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian reactivation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian reactivation Poor ovarian response

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IVIRMA Alicante

    Alicante, Alicante, 03015, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.